GlassScriptPhysician profile
Aimee Gintera Newsom
NPI 1043695570
$4,871.97
in general payments reported to CMS, 2019-2025
43 companies · $973 in 2025
The $973 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,476 · 2022: $797 · 2023: $843 · 2024: $783 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $785.39 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $683.16 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Dexcom, INC. | $421.73 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $359.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $337.86 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $252.14 | 2021-2025 | |
| Astellas Pharma US INC | $177.39 | 2021-2025 | Veozah |
| Pfizer INC. | $164.78 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $152.90 | 2022-2025 | Keveyis, Gvoke Hypopen |
| Amarin Pharma, INC. | $119.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $109.16 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $97.40 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $93.62 | 2021-2024 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.15 | 2025 | Caplyta |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $73.75 | 2025 | Korlym |
| Vivus LLC | $73.53 | 2021 | |
| Merck Sharp & Dohme LLC | $62.44 | 2021-2025 | Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $60.12 | 2022 | |
| Exact Sciences Corporation | $59.01 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.77 | 2024-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $54.61 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $46.24 | 2021-2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $44.44 | 2022-2023 | Onpattro |
| Optinose US, INC. | $40.62 | 2021 | |
| Abbott Laboratories | $40.34 | 2022-2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $34.24 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lundbeck LLC | $31.84 | 2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $26.26 | 2021 | |
| Abiomed | $24.85 | 2025 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Renalytix Ai, INC. | $20.96 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $20.64 | 2022 | |
| Vital Connect, INC | $16.47 | 2022 | |
| Eisai INC. | $16.36 | 2021 | |
| Stryker Corporation | $15.68 | 2025 | Clottriever Bold Catheter |
| Biogen, INC. | $14.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $13.90 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.43 | 2021 | |
| Vistapharm, INC. | $13.13 | 2021 | |
| Seqirus USA INC | $12.53 | 2021 | |
| Allergan, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Newsom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.